JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

Using AI, we identified baricitinib as having antiviral and anticytokine efficacy. We now show a 71% (95% CI 0.15 to 0.58) mortality benefit in 83 patients with moderate-severe SARS-CoV-2 pneumonia with few drug-induced adverse events, including a large elderly cohort (median age, 81 years). An addi...

Descripción completa

Detalles Bibliográficos
Autores principales: Stebbing, Justin, Sánchez Nievas, Ginés, Falcone, Marco, Youhanna, Sonia, Richardson, Peter, Ottaviani, Silvia, Shen, Joanne X., Sommerauer, Christian, Tiseo, Giusy, Ghiadoni, Lorenzo, Virdis, Agostino, Monzani, Fabio, Rizos, Luis Romero, Forfori, Francesco, Avendaño Céspedes, Almudena, De Marco, Salvatore, Carrozzi, Laura, Lena, Fabio, Sánchez-Jurado, Pedro Manuel, Lacerenza, Leonardo Gianluca, Cesira, Nencioni, Caldevilla Bernardo, David, Perrella, Antonio, Niccoli, Laura, Méndez, Lourdes Sáez, Matarrese, Daniela, Goletti, Delia, Tan, Yee-Joo, Monteil, Vanessa, Dranitsaris, George, Cantini, Fabrizio, Farcomeni, Alessio, Dutta, Shuchismita, Burley, Stephen K., Zhang, Haibo, Pistello, Mauro, Li, William, Romero, Marta Mas, Andrés Pretel, Fernando, Simón-Talero, Rafaela Sánchez, García-Molina, Rafael, Kutter, Claudia, Felce, James H., Nizami, Zehra F., Miklosi, Andras G., Penninger, Josef M., Menichetti, Francesco, Mirazimi, Ali, Abizanda, Pedro, Lauschke, Volker M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775747/
https://www.ncbi.nlm.nih.gov/pubmed/33187978
http://dx.doi.org/10.1126/sciadv.abe4724

Ejemplares similares

Ejemplares similares